Sarepta Therapeutics (SRPT) Accumulated Expenses (2010 - 2026)

Sarepta Therapeutics' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $32.9 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 91.61% year-over-year to $32.9 million; the TTM figure through Mar 2026 stood at $32.9 million (down 91.61% YoY), while the FY2025 annual figure was $359.7 million, up 294.71% from the prior year.
• Accumulated Expenses was $32.9 million for Q1 2026 at Sarepta Therapeutics, down from $359.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $391.6 million in Q1 2025 to a low of $1.1 million in Q2 2022.
• Historically, Accumulated Expenses has averaged $143.9 million across 5 years, with a median of $65.9 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses tumbled 99.55% in 2022, then jumped 9707.45% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $65.9 million in 2022, then climbed by 19.39% to $78.7 million in 2023, then increased by 15.73% to $91.1 million in 2024, then surged by 294.71% to $359.7 million in 2025, then tumbled by 90.86% to $32.9 million in 2026.
• The last three Accumulated Expenses figures came in at $32.9 million (Q1 2026), $359.7 million (Q4 2025), and $295.8 million (Q3 2025), per Business Quant data.